Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

156.15 -1.10 (-0.70%)
Official Closing Price Updated: 7:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Why Traders Are Buying the Dip on Johnson & Johnson Stock
Shares of Johnson & Johnson stock have declined by 11.5% in the quarter, and markets are calling for a bottom and rally here. 
Via MarketBeat
These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024
Via The Motley Fool
Topics Stocks
Exposures US Equities
Abbott Laboratories Will Outperform Healthcare Stocks in 2025
Johnson & Johnson and Abbott Laboratories offer substantial opportunities for investors, but one is a better buy for total returns in 2025 and 2026. 
Via MarketBeat
Where Johnson & Johnson Stands With Analysts
Via Benzinga
5 of the Safest High-Yield Dividend Stocks You Can Confidently Buy for 2025
Five magnificent income stocks -- sporting an average yield of 4.26% -- can pad investors' pocketbooks in the new year (and well beyond). 
Via The Motley Fool
Stocks Going Ex Dividend In February 2025
This article features a short list of some of the many stocks going ex-dividend during the next month, which can be helpful for traders and investors 
Via Talk Markets
Topics Stocks / Equities
Up About 62% in a Year, Can Intuitive Surgical Stock Keep Soaring?
Via The Motley Fool
Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst
Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments. 
Via Benzinga
This Is 1 of the Healthiest High-Yielding Dividend Stocks You'll Find
Via The Motley Fool
Earnings Picture Remains Strong: A Closer Look
Total earnings for the 62 S&P 500 companies that have reported results are up +19.6% from the same period last year on +8.4% higher revenues, with 82.3% beating EPS estimates and 69.4% beating revenue... 
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
S&P 500 Hits Fresh Records At 6,100: Strong Earnings, Trump's AI Wager Fuel Bull Run
Market surges on AI Stargate initiative & strong earnings. S&P 500 hits record high of 6,100 points, led by tech giants & semiconductor stocks. 
Via Benzinga
Topics Artificial Intelligence Government Stocks
Exposures Artificial Intelligence Political US Equities
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals. 
Via Benzinga
Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript
JNJ earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Chipmakers Rally On AI Stargate Bet, Netflix Soars, Bitcoin Falters As Trump Keeps Quiet On Crypto: What's Driving Markets Wednesday?
Tech stocks enjoyed a surge Wednesday, driven by a sharp rise in semiconductor shares after President Donald Trump, OpenAI's Sam Altman, Oracle Corp. 
Via Benzinga
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Johnson & Johnson Q4 Earnings And Revenues Top Estimates
Johnson & Johnson came out with quarterly earnings of $2.04 per share. 
Via Talk Markets
Topics Stocks / Equities
J&J Stock Dips As 2025 Sales Guidance Misses Estimate, But Retail Mood Resilient
During the earnings call, J&J highlighted several growth drivers, including its positioning for 5%-7% annual growth through 2030 and plans to increase its dividend annually. 
Via Stocktwits
Topics Earnings
Exposures Financial
Johnson & Johnson Tops Q4 EPS Forecasts
Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations. 
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
Johnson & Johnson Q4 Earnings: Cancer Drugs Performance Drives Revenue Beat, Issues Strong FY25 Outlook
Johnson & Johnson's Q4 sales hit $22.52 billion, with strong growth in MedTech and oncology. 2025 guidance shows promising EPS and revenue forecasts. 
Via Benzinga
Johnson & Johnson Earnings Narrowly Top But Dow Giant's Sales Guidance Light
The Dow Jones stock fell slightly early Wednesday. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Johnson & Johnson Reports Q4 and Full-Year 2024 Results
From Johnson & Johnson
Via Business Wire
US Stocks Likely To Open Higher As President Trump Announces $500 Billion AI Project: Oracle, Netflix, Nvidia Among Top Stocks To Watch
U.S. stocks could open on a positive note on Wednesday, continuing to rally after Donald Trump's inauguration as the 47th President of the U.S. on Monday. 
Via Benzinga
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Earnings Scheduled For January 22, 2025
Via Benzinga
Dow Jumps Over 500 Points As Trump Takes Office: Investor Sentiment Improves, But Greed Index Remains In 'Fear' Zone
The CNN Business Fear & Greed Index measures market sentiment, with higher fear putting pressure on stocks. 
Via Benzinga
Topics Government Stocks
Exposures Political US Equities
Netflix, Procter & Gamble And 3 Stocks To Watch Heading Into Wednesday
Via Benzinga
Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Via Benzinga
Big Trading Day Ends With Q4 Earnings Beats: NFLX, UAL, COF
Markets had a strong session on the first full day of President Trump’s second administration. Indexes have rocketed up from 2025 lows hit a week to a week and a half ago. 
Via Talk Markets
Topics Government Stocks / Equities
Exposures Political
Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse?
JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price target - 13% upside 
Via Benzinga
Exposures Product Safety
Johnson & Johnson Q4 Preview: Can Earnings Bring Health Care 'Back To Life'?
Johnson & Johnson is one of several Dow Jones Industrial Average stocks reporting financial results this week. A look at the key items and numbers to watch. 
Via Benzinga
Topics Stocks
Exposures US Equities
FDA Approves Johnson & Johnson's Treatment As First Monotherapy For Treatment-Resistant Depression
FDA approves Johnson & Johnson's Spravato nasal spray as a monotherapy for major depressive disorder, showing superior efficacy in clinical trials. 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.